arrow
C

Corinne Summers

university of washington
H指数:18
被引数:2,167

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genome-wide CRISPRa screens identify modulators of CAR T survival across diverse tumor cytokine milieus

全基因组CRISPRa筛选鉴定了在多样化肿瘤细胞因子微环境中调节CAR T细胞存活的调控因子

2026-09-280
OAAI
Intracerebroventricular B7-H3-targeting chimeric antigen receptor T cells for non-pontine diffuse midline glioma and recurrent/refractory pediatric CNS tumors: A phase 1 trial

脑室内B7-H3靶向嵌合抗原受体T细胞治疗非脑桥弥漫性中线胶质瘤和复发/难治性儿童中枢神经系统肿瘤:一项1期临床试验

2026-07-250
PRE
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer

CAR T细胞治疗在儿童、青少年和青年癌症患者中的典型作用

2026-01-230
PRE
Post Hematopoietic Cell Transplantation Maintenance Therapy with Low-Dose Azacitidine in a Pediatric Population with High-Risk Myeloid Malignancies

造血干细胞移植后低剂量阿扎胞苷维持治疗在具有高风险髓系恶性肿瘤的儿科人群中的应用

2025-12-050
PRE
Outcomes following hematopoietic cell transplantation for children, adolescents and young adults with relapsed acute lymphoblastic leukemia

儿童、青少年和年轻成人复发急性淋巴细胞白血病造血细胞移植后的结局

2025-11-160
PRE
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia

外周血计数低和升高的促炎细胞因子预示急性淋巴细胞白血病中CD19嵌合抗原受体T细胞反应不良

2025-05-200
OAAI
Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL

PLAT-02和PLAT-03的研究结果:评估CD19 CAR T细胞疗法及CD19表达T-APC支持在儿童B-ALL中的应用

Blood
IF23.1
2025-04-170
PRE
Decreasing chronic graft-versus-host disease rates in all populations
2024-11-150
OAAI
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia

启发研讨会第二部分: 预防和治疗b细胞急性淋巴细胞白血病的嵌合抗原受体T细胞治疗后的复发

2023-11-016
OAAI
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage

CD19嵌合抗原受体T细胞诱导的急性淋巴细胞白血病缓解后的造血细胞移植赋予无白血病生存优势

2022-01-0143
OAAI